Free Trial

Mathew Blackman Analyst Performance

Analyst at Stifel Nicolaus

Mathew Blackman is a stock analyst at Stifel Nicolaus in the medical sector, covering 12 publicly traded companies. Over the past year, Mathew Blackman has issued 9 stock ratings, including buy and hold recommendations. While full access to Mathew Blackman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Mathew Blackman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
19 Last 8 Years
Buy Recommendations
63.16% 12 Buy Ratings
Companies Covered
12 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy63.2%12 ratings
Hold36.8%7 ratings
Sell0.0%0 ratings

Out of 19 total stock ratings issued by Mathew Blackman at Stifel Nicolaus, the majority (63.2%) have been Buy recommendations, followed by 36.8% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
83.3% of companies on NASDAQ
10 companies
NYSE
16.7% of companies on NYSE
2 companies

Mathew Blackman, an analyst at Stifel Nicolaus, currently covers 12 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
12 companies
100.0%

Mathew Blackman of Stifel Nicolaus specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED INSTRUMENTS
6 companies
50.0%
MED PRODUCTS
3 companies
25.0%
SURGICAL & MEDICAL INSTRUMENTS
2 companies
16.7%
SURGICAL APPLIANCES & SUPPLIES
1 company
8.3%

Mathew Blackman's Ratings History at Stifel Nicolaus

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
8/1/2025Boost Price Target$10.11$9.00Buy
Inogen, Inc stock logo
INGN
Inogen
5/8/2025Lower Price Target$5.99$7.00Hold
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
5/1/2025Lower Price Target$19.66$31.00Buy
Penumbra, Inc. stock logo
PEN
Penumbra
4/24/2025Set Price Target$277.24$318.00Buy
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
4/1/2025Boost Price Target$11.89$25.00Buy
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
2/24/2025Initiated Coverage$20.57$25.00Buy
Insulet Corporation stock logo
PODD
Insulet
2/21/2025Boost Price Target$282.42$293.00Hold
Globus Medical, Inc. stock logo
GMED
Globus Medical
2/21/2025Boost Price Target$82.11$94.00Buy
Cerus Corporation stock logo
CERS
Cerus
10/17/2024Lower Price Target$1.47$3.00Buy